Menu
Close
Global
×

Company News

Company News
Company News
2025-10-31
Positive Progress of Amulirafusp Alfa (IMM0306) in the Treatment of Systemic Lupus Erythematosus (SLE) Presented at ACR Convergence 2025
On October 28, 2025, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco," with the stock code 01541.HK on the Hong Kong Stock Exchange) presented the latest results of the Phase
View more
2025-10-02
Application for Phase III Clinical Trial of IMM2510 for IO-Resistant Non-Small Cell Lung Cancer Submitted to CDE
Application for Phase III Clinical Trial of IMM2510 for IO-Resistant Non-Small Cell Lung Cancer Submitted to CDE
View more
2025-09-17
Application for the Phase III Clinical Trial of IMM0306 for the Treatment of Follicular Lymphoma
Application for the Phase III Clinical Trial of IMM0306 for the Treatment of Follicular Lymphoma
View more
2025-09-16
Important Milestone | IMM2510 (VEGF×PD-L1) Two Phase III Registration Clinical Trials Have Submitted EOP2 Innovative Therapy Enters Key Stage
IMM2510 has submitted End-of-Phase 2 (EOP2) communication applications for two Phase III registration clinical trials targeting different types of lung cancer to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).
View more
2025-09-09
IMM2510 Shows Breakthrough Potential in IO-Resistant Squamous NSCLC at WCLC 2025
IMM2510, an Anti-PD-L1/VEGF Bispecific Antibody Fusion Protein for Advanced IO-treated SQ-NSCLC: A Phase I Study
View more
2025-08-28
Milestone Payment of $5 Million Received for IMM2510 and IMM27M Collaboration between ImmuneOnco and Instil Bio
Milestone Payment of $5 Million Received for IMM2510 and IMM27M Collaboration between ImmuneOnco and Instil Bio
View more
总计 78 12345678...1213